Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

TAVR Is Real (And Maybe Spectacular), But Edwards Lifesciences Isn't A Bargain

Once again I seem to have underestimated how Wall Street's love of a good story can overpower and outweigh the likely long-term economic returns from that story. In the case of Edwards Lifesciences (NYSE:EW), I have never doubted that transcatheter aortic valve replacement (TAVR) (also called "... valve implantation" or TAVI) was going to be successful, nor that Edwards' Sapien would be a major player.

What I doubted was whether Wall Street would keep pumping up the valuation it was willing to pay. With Edwards being one of the relatively few double-digit organic growth stories in med-tech, the stock is up about 30% since my last skeptical piece - not all that much better than other med-tech names...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details